Immix Biopharma, Inc. (IMMX) Free Cash Flow
Immix Biopharma, Inc. (IMMX) free cash flow history and trends. Track FCF in Excel with MarketXLS.
Free Cash Flow Data
| Period | Free Cash Flow (USD) |
|---|---|
| 2021-12-31 | -$1.59M |
| 2022-12-31 | -$7.41M |
| 2023-12-31 | -$11.42M |
| 2024-12-31 | -$15.77M |
| 2025-12-31 | -$24.66M |
How IMMX compares with sector peers
| Symbol | Company | Free cash flow (latest fiscal year) |
|---|---|---|
| STIM | Neuronetics Inc. | -$21.18M |
| NEO | NeoGenomics Inc. | -$21.78M |
| DMAC | DiaMedica Therapeutics Inc. | -$29.10M |
| ATOS | Atossa Therapeutics Inc. | -$29.79M |
| VERU | Veru Inc. | -$30.04M |
These are five companies in the same sector as IMMX with a comparable annual free cash flow. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Immix Biopharma, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Free_Cash_Flow("IMMX", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | IMMX | $13.61 | -0.37% | 1.41M |
| 3 | ||||
| 4 | ||||
| 5 |